Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human TLR2 aa 1-600 (extracellular).
(Peptide available as
This product is a recombinant rabbit monoclonal antibody.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated ‘PUR’ on our product labels.
If you have any questions regarding this update, please contact our Scientific Support team.
This antibody was developed as part of a collaboration between Epitomics, the National Cancer Institute's Center for Cancer Research and the lab of David Segal. Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.
Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.
Our Abpromise guarantee covers the use of ab108998 in the following tested applications.
|WB||1/1000 - 1/10000. Detects a band of approximately 90 kDa (predicted molecular weight: 90 kDa).
Recommend using the positive control of LPS stimulated THP1 cells, as the signal can be very weak in some tissues or cells. Recommend diluting antibody in 1% BSA for better results.
This blot was produced using a 10% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab108998 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution.
Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST